Skip to main content
Log in

Prognostic significance of Ki‐67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

To evaluate the prognostic relevance of Ki‐67 and topoisomerase IIα expression in relation to tumor stage, grade, and hormone receptor content, 942 ductal infiltrating carcinomas of the breast were examined by means of the monoclonal antibodies Ki‐S11 (Ki‐67) and Ki‐S4 (topoisomerase IIα). pS2, c‐erbB2, and p53 were additionally considered as prognostic variables. The median follow‐up time was 149 months. Eight‐hundred‐and‐sixty‐three tumors reacted with Ki‐S11 and Ki‐S the labeling indices of the two antigens were closely associated (r=0.93). Both correlated positively with the tumor size, c‐erbB2, and p53 expression, and negatively with patient age, hormone receptor content, and pS2 immunostaining. In the univariate analysis, Ki‐S11 and Ki‐S4 scores, nodal status, tumor size, tumor grade, and progesterone receptor content strongly predicted both overall and metastasis‐free survival (p <0.00001). Estrogen receptor status, p53, and c‐erbB2 were of minor significance. Concerning overall survival, multivariate Cox regression analysis selected a Ki‐S4 score >25% (p < 0.00001) next to the nodal status, and before tumor size, progesterone receptor content, and patient age. Independent predictors of the occurrence of distant metastases were nodal status, Ki‐S4, tumor size, grade 1, and progesterone receptor negativity, in that order. The Ki‐S11 score was of independent prognostic significance only if examined as a continuous variable. We conclude that topoisomerase IIα expression as assessed by monoclonal antibody Ki‐S4 may add valuable information to current prognostic models for breast cancer. Its predictive value appears to be essentially related to the proliferative activity of tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hedley DW, Rugg CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of node-positive early breast cancer. Cancer Res 47: 4729–4735, 1987

    Google Scholar 

  2. Merkel DE, Winchester DJ, Goldschmidt RA, August CZ, Wruck DM, Rademaker AW: DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph nodenegative breast cancer. Cancer 72: 1926–1932, 1993

    Google Scholar 

  3. Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL, Wold LE, Grant C, Gonchoroff NJ, Katzmann JA: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node-negative breast cancer: Cancer 74: 1752–1761, 1994

    Google Scholar 

  4. Gasparini G, Boracchi P, Verderio P, Bevilacqua P: Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57: 822–829, 1994

    Google Scholar 

  5. Stal O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist LE, Skoog L, Sullivan S, Wingren S, Nordenskjold B: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 11: 1717–1722, 1993

    Google Scholar 

  6. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J NatI Cancer Inst 84: 1266–1272, 1992

    Google Scholar 

  7. Lipponen P, Eskelinen M, Papinaho S, Klemi PJ, Aaltomaa S, Kosma VM, Mann S, Syrjanen K: Sex steroid receptors, Sphase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. Anticancer Res 12: 677–682, 1992

    Google Scholar 

  8. Sampson SA, Kreipe H, Gillett CE, Smith P, Chaudary MA, Khan A, Wicks K, Parwaresch R, Barnes DM: KiS1 – a novel monoclonal antibody which recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 168: 179–185, 1992

    Google Scholar 

  9. Kreipe H, AIm P, Olsson H, Hauberg M, Fischer L, Parwaresch R: Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 142: 651–657, 1993

    Google Scholar 

  10. Rudas M, Gnant MF, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res Treat 32: 165–175, 1994

    Google Scholar 

  11. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931, 1993

    Google Scholar 

  12. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa AP, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: Its prognostic value on short-term recurrences. Eur J Cancer 29A: 1509–1513, 1993

    Google Scholar 

  13. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K: The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122: 687–692, 1996

    Google Scholar 

  14. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57–64, 1996

    Google Scholar 

  15. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Janicke F, Nathrath W, Schmitt M, Graeff H, Hofler H: Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75: 1525–1533, 1997

    Google Scholar 

  16. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984

    Google Scholar 

  17. Gerdes J, Li L, Schlüter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad H-D: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1384: 867–873, 1991

    Google Scholar 

  18. Schwarting R: Little missed markers and Ki-67. Lab Invest 68(6): 597–599, 1993

    Google Scholar 

  19. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2: 209–214, 1991

    Google Scholar 

  20. Watanabe M, Tsutsui K, Inoue Y: Differential expressions of the topoisomerase II alpha and II beta mRNAs in developing rat brain. Neurosci Res 19: 51–57, 1994

    Google Scholar 

  21. Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T, Wacker HH, Domanowski M, Seidel A, Westergaard O, Parwaresch R: Detection of topoisomerase II alpha in cell lines and tissues – characterization of five novel monoclonal antibodies. J Histochem Cytochem 45: 251–263, 1997

    Google Scholar 

  22. Lynch BJ, Guinee DG Jr, Holden JA: Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer [In Process Citation]. Hum Pathol 28: 1180–1188, 1997

    Google Scholar 

  23. Wang JC: Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1–9, 1987

    Google Scholar 

  24. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M: DNA topoisomerase is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50: 917–925, 1987

    Google Scholar 

  25. Wang JC: DNA topoisomerases as targets of therapeutics: An overview. Adv Pharmacol 29: 1–19, 1994

    Google Scholar 

  26. Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P: Breast cancerassociated pS2 protein: Synthesis and secretion by normal stomach mucosa. Science 241: 705–708, 1988

    Google Scholar 

  27. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P: Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 12: 2861–2878, 1984

    Google Scholar 

  28. Foekens JA, Rio MC, Seguin P, van Putten WL, Fauque J, Nap M, Klijn JG, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832–3837, 1990

    Google Scholar 

  29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    Google Scholar 

  30. Guérin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB2 and EGF receptor genes in inflammatory and noninflammatory breast cancer: Prognostic significance. Int J Cancer 43: 201–208, 1989

    Google Scholar 

  31. Bacus SS, Zelnick CR, Plowman G, Yarden Y: Expression of the erbB2 family of growth factor receptors and their ligands in breast cancers: Implication for tumor biology and clinical behavior. Am J Clin Pathol 102: S13–S24, 1994

    Google Scholar 

  32. Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ: The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 16: 3141–3147, 1996

    Google Scholar 

  33. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helm HH, Isola JJ: Association of c-erbB2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991

    Google Scholar 

  34. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991

    Google Scholar 

  35. Quénel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: The prognostic value of cerbB2 in primary breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 35: 283–291, 1995

    Google Scholar 

  36. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109–1114, 1992

    Google Scholar 

  37. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51–56, 1993

    Google Scholar 

  38. Silvestrini R, Benini F, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604–1610, 1996

    Google Scholar 

  39. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ: Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int J Cancer 69: 135–141, 1996

    Google Scholar 

  40. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study of 942 cases. Breast Cancer Res Treat 36: 71–81, 1995

    Google Scholar 

  41. Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R, Coindre JM: Prognostic relevance of a novel proliferation marker, Ki-S11, for soft tissue sarcoma: A multivariate study. Am J Pathol 150: 1997–2007, 1997

    Google Scholar 

  42. Rudolph P, Heidebrecht H-J, Kellner U, Seidel A, Parwaresch MR: Proliferation marker Ki-S1 binds to a formalin-resistant epitope of topoisomerase II. Int J Surg Pathol 2: 388, 1995 (Abstract)

    Google Scholar 

  43. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H: Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha: Delineation of a carboxyterminal epitope with peptide antibodies. Am J Pathol 146: 1302–1308, 1995

    Google Scholar 

  44. de Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM: Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Appl Immunohistochem: 3: 222–231, 1995

    Google Scholar 

  45. MacGrogan G, Soubeyran I, de Mascarel I, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM: Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: A correlative study of 942 cases. Appl Immunohistochem 4: 219–227, 1996

    Google Scholar 

  46. Soubeyran I, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 34: 119–128,1995

    Google Scholar 

  47. Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JR: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970–976, 1992

    Google Scholar 

  48. Kreipe H, Heidebrecht HJ, Hansen S, Rohlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ, Parwaresch R: A new proliferation-associated nuclear antigen detectable in paraffinembedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142: 3–9, 1993

    Google Scholar 

  49. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M: c-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N EngI J Med 330: 1260–1266, 1994

    Google Scholar 

  50. Ravdin PM, Chamness GC: The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers – a review. Gene 159: 19–27, 1995

    Google Scholar 

  51. Soubeyran I, Quénel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer patients. Br J Cancer 74: 1120–1125, 1996

    Google Scholar 

  52. Levine AJ: The p53 tumor suppressor gene (editorial). N EngI J Med 326: 1350–1352, 1992

    Google Scholar 

  53. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299, 1997

    Google Scholar 

  54. Eder JP Jr, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE: DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 55: 6109–6116, 1995

    Google Scholar 

  55. Järvinen TAH, Kononen J, Pelto-Huikko M, Isola J: Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148: 2073–2082, 1996

    Google Scholar 

  56. Rudolph P, Knüchel R, Endl E, Heidebrecht HJ, Hofstädter F, Parwaresch R: The immunohistochemical marker Ki-S2: Tissue distribution and cell cycle kinetics of a novel proliferationspecific antigen. Mod Pathol 1998 (In Press)

  57. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 73: 1518–1524, 1996

    Google Scholar 

  58. Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62: 513–515, 1979

    Google Scholar 

  59. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383–1387, 1989

    Google Scholar 

  60. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681–683, 1992

    Google Scholar 

  61. Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71: 1029–1032, 1995

    Google Scholar 

  62. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB2, MiB1, pS2 and GSTpi. Br J Cancer 74: 1458–1465, 1996

    Google Scholar 

  63. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Giunchi DC, Vio A, Saragoni A, Silvestrini R: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. Breast Cancer Res Treat 43: 7–14, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rudolph, P., MacGrogan, G., Bonichon, F. et al. Prognostic significance of Ki‐67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 55, 61–71 (1999). https://doi.org/10.1023/A:1006159016703

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006159016703

Navigation